Moleculin Biotech Stock Performance
| MBRX Stock | USD 1.09 0.05 4.81% |
Moleculin Biotech holds a performance score of 3 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 4.12, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Moleculin Biotech will likely underperform. Use Moleculin Biotech maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Moleculin Biotech.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Moleculin Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Moleculin Biotech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 43.1 M |
Moleculin |
Moleculin Biotech Relative Risk vs. Return Landscape
If you would invest 173.00 in Moleculin Biotech on December 22, 2024 and sell it today you would lose (64.00) from holding Moleculin Biotech or give up 36.99% of portfolio value over 90 days. Moleculin Biotech is currently generating 1.4594% in daily expected returns and assumes 29.2409% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Moleculin, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Moleculin Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moleculin Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moleculin Biotech, and traders can use it to determine the average amount a Moleculin Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0499
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | MBRX | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 29.24 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.46 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Moleculin Biotech is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moleculin Biotech by adding it to a well-diversified portfolio.
Moleculin Biotech Fundamentals Growth
Moleculin Stock prices reflect investors' perceptions of the future prospects and financial health of Moleculin Biotech, and Moleculin Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moleculin Stock performance.
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 5.48 M | ||||
| Shares Outstanding | 13.3 M | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 1.94 X | ||||
| EBITDA | (29.5 M) | ||||
| Cash And Equivalents | 58 M | ||||
| Cash Per Share | 2.03 X | ||||
| Total Debt | 574 K | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 2.49 X | ||||
| Cash Flow From Operations | (24.1 M) | ||||
| Earnings Per Share | (12.04) X | ||||
| Total Asset | 38.22 M | ||||
| Retained Earnings | (131.6 M) | ||||
| Current Asset | 28.09 K | ||||
| Current Liabilities | 772.79 K | ||||
About Moleculin Biotech Performance
Evaluating Moleculin Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Moleculin Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Moleculin Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.Things to note about Moleculin Biotech performance evaluation
Checking the ongoing alerts about Moleculin Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moleculin Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Moleculin Biotech is way too risky over 90 days horizon | |
| Moleculin Biotech has some characteristics of a very speculative penny stock | |
| Moleculin Biotech appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (29.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Moleculin Biotech currently holds about 58 M in cash with (24.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Moleculin Biotech has a poor financial position based on the latest SEC disclosures |
- Analyzing Moleculin Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moleculin Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Moleculin Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Moleculin Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moleculin Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Moleculin Biotech's stock. These opinions can provide insight into Moleculin Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.